Skip to main content
SpringerLink
Log in

Animal models for the study of atypical anti-inflammatory agents

  • Experimental Models of Inflammation
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

In contrast to the approach focusing on aspirin and cortisone as models for research, a physiopathologically-oriented approach provides the rationale for developing animal models suitable for detecting anti-inflammatory agents with a profile of therapeutic and side effects unlike that of currently used drugs.

The so-called ‘primary’ anti-inflammatory agents have a marked efficacy in animal models of acute inflammation and lack significant anti-PG effects. Clinically, they relieve the symptoms of acute inflammatory conditions, both topically and systemically, are practically inactive in rheumatic disorders and have a profile of side-effects different from that of aspirin or cortisone. Available data suggest that their characteristic profile of side and therapeutic effects reflect qualitative, rather than quantitative differences, from aspirin and cortisone.

The so-called ‘secondary’ anti-inflammatory agents affect the conditioning factors for some inflammatory diseases, including rheumatoid arthritis, rather than the inflammatory process itself. Besides the derangement of the immune system and the consequent development of immunomodulators, the role of specific protein changes as a conditioning factor is discussed and animal models are illustrated focusing on this phenomenon. The possibility is also discussed that protein denaturation is not only responsible for the formation of new antigenic determinants, but also for necrotic lesions accompanying some inflammatory disorders. Results obtained with animal models of conditioned inflammation with marked necrotic lesions are presented. The interest for this approach is that conditioning factors for inflammation appear a more specific target for drug treatment, rather than inflammation itself.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. C.A. Winter, E.A. Risley andG.W. Nuss,Anti-inflammatory and antipyretic activities of indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid, J. Pharmacol. exp. Ther.141, 369 (1963).

    PubMed  Google Scholar 

  2. B. Silvestrini, General implications from a study on the anti-inflammatory activity of benzydamine. InNon-Steroidal Anti-Inflammatory Drugs, Int. Congr. Series no. 82, pp. 180–189 (EdsS. Garattini andM.N.G. Dukes). Excerpta Medica, Amsterdam 1965.

    Google Scholar 

  3. B. Silvestrini, A. Garau, C. Pozzatti andV. Cioli,Pharmacological research on benzydamine — a new analgesic anti-inflammatory drug, Arzneim. Forsch.16, 59–63 (1966).

    Google Scholar 

  4. T.M. Gilfoil, I. Klavins andL. Grumbach,Effects of acetylsalicylic acid on the edema and hyperesthesia of the experimentally inflamed rat's paw, J. Pharmacol. exp. Ther.142, 1 (1963).

    PubMed  Google Scholar 

  5. J. Weis,Investigations on some experimental inflammations in mouse paws, Med. Exp. (Basel)8, 1 (1963).

    Google Scholar 

  6. C.V. Winder, J. Wax, V. Burr, M. Been andC.E. Rosiere,A study of pharmacological influences on ultraviolet erythema in guinea pigs, Arch. int. Pharmacodyn116, 261 (1958).

    PubMed  Google Scholar 

  7. E.M. Bavin, D.J. Drain, D.E. Seymour andP.D. Waterhouse,Anti-inflammatory compounds. Part I. The activity of a series of new compounds compared with phenylbutazone and cortisone, J. Pharm. Pharmacol.7, 1022 (1955).

    PubMed  Google Scholar 

  8. J.R. Boissier, J.M. Lwoff andF. Hertz,Action comparee de six anti-infiammatoires non steroidiques, Therapie25, 43 (1970).

    PubMed  Google Scholar 

  9. P.F. D'Arcy, E.M. Howard, P.W. Muggleton andS.B. Townsend,The anti-inflammatory action of griseofulvin in experimental animals, J. Pharm. Pharmacol.12, 659 (1960).

    PubMed  Google Scholar 

  10. K.F. Swingle, T.J. Grant andD.C. Kvam,Quantal responses in the Randal Selitto Assay, Exp. Biol. and Med.137, 536 (1971).

    Google Scholar 

  11. B.B. Newbould,Suppression of adjuvant-induced arthritis in rats with 2-butoxycarbonyl-methylene-4-oxo-thiazolidine, Brit. J. Pharmacol.24, 632 (1965).

    Google Scholar 

  12. B. Silvestrini, Working hypothesis exploited in the pharmacological research of some anti-inflammatory drugs. InInflammation, p. 26 (EdsB. Silvestrini, S. Tura andW.G. Spector). Excerpta Medica Foundation, Amsterdam 1968.

    Google Scholar 

  13. L.O. Randall andJ.J. Selitto,A method for measurement of analgesic activity on inflamed tissue, Arch. Int. Pharmacodyn.111, 409 (1957).

    PubMed  Google Scholar 

  14. S. Tsurufuji, H. Sato, K.R. Min andK. Ohuchi,Difference in the anti-inflammatory effect of indomethacin between acute and chronic stages of carrageenin-induced inflammation, J. Pharm. Dyn.1, 8–14 (1978).

    Google Scholar 

  15. M. Di Rosa, J.P. Giroud andD.A. Willoughby Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenin and turpentine, J. Path.104, 15–29 (1971).

    Article  PubMed  Google Scholar 

  16. M. Di Rosa andD.A. Willoughby,Screens for anti-inflammatory drugs, J. Pharm. Pharmac.23, 297–298 (1971).

    Google Scholar 

  17. D.F. Woodward, M.A. Pipkin, P. Raval andD.A.A. Owen,Effect of histamine H 1-and H 2-receptor antagonists, steroidal and non-steroidal anti-inflammatory agents on carrageenin-induced inflammation of the guinea-pig ear, Arch. int. Pharmacodyn.257, 295–306 (1982).

    PubMed  Google Scholar 

  18. S.I. Ankier andM.S. Starr,The importance of plasma kinins in the anaphylactoid reaction in rats, Br. J. Pharmac.31, 331–339 (1967).

    Google Scholar 

  19. J.R. Parrat andG.B. West,Inhibition by various substances of oedema formation in the hind-paw of the rat induced by 5-hydroxytryptamine, histamine, dextran, egg white and compound 48/80, Br. J. Pharmac.13, 65–70 (1958).

    Google Scholar 

  20. D.A. Owen, E. Poy andD.F. Woodward,Evaluation of the role of histamine H 1 and H 2 receptors in cutaneous inflammation in the guinea-pig produced by histamine and mast cell degranulation, Br. J. Pharmac.69, 615–623 (1980).

    Google Scholar 

  21. V. Cioli, D. Piccinelli andS. Putzolu, Animal studies on the ulcerogenic action of anti-inflammatory drugs. InDrugs and Peptic Ulcer, vol. 2, pp. 44–54 (Ed.C.J. Pfeiffer). CRC Press, Inc. Boca Raton, Florida 1982.

    Google Scholar 

  22. R. Lisciani, P. Scorza Barcellona andB. Silvestrini,Researches on the topical activity of benzydamine, Europ. J. Pharmacol.3, 157 (1968).

    Article  Google Scholar 

  23. V. Cioli, C. Corradino andP. Scorza Barcellona,Review of pharmacological data on benzydamine, in press in Tissue Reactions (1985).

  24. K. Tsurumi, Y. Hiramatsu, M. Nozaki, M. Hayashi andH. Fujimura,Anti-inflammatory activity of tiaramide hydrochloride, 4-(5-chloro-2-oxo-benzothiazolinyl) acetyl-1-piperazine ethanol hydrochloride, Arzneim. Forsch.22, 716 (1972).

    Google Scholar 

  25. K. Goto, M. Hisadome andH. Imamura,Effects of tinoridine on stability of rat liver and kidney lysosomes and liver parenchymal cells, Biochem. Pharmacol.26, 11 (1977).

    Article  PubMed  Google Scholar 

  26. B. Silvestrini, A. Garau, C. Pozzatti, V. Cioli andB. Catanese,Additional pharmacological studies on benzydamine, Arch. Int. Pharmacodyn.163, 61 (1966).

    PubMed  Google Scholar 

  27. P. Görög andI.B. Kovaćs, The alteration of platelet behaviour during various conditions and the effect of anti-inflammatory agents on platelet aggregation and thrombus formation. InInflammation, Biochemistry and Drug Interaction, p. 197 (EdsA. Bertelli andJ.C. Houck). Excerpta Medica Foundation, Amsterdam 1969.

    Google Scholar 

  28. Y. Ōyanagui,Inhibition of superoxide anion production in macrophages by anti-inflammatory drugs, Biochem. Pharmacol.25, 1473 (1976).

    Article  PubMed  Google Scholar 

  29. Y. Ōyanagui,Inhibition of superoxide anion production in non-stimulated guinea-pig peritoneal exudate cells by anti-inflammatory drugs, Biochem. Pharmacol.27, 777 (1978).

    Article  PubMed  Google Scholar 

  30. S. Moncada, P. Needleman, S. Bunting andJ.R. Vane,Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition, Prostaglandins12, 323 (1976).

    Article  PubMed  Google Scholar 

  31. R.J. Flower, H.S. Cheung andD.W. Cushman,Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle, Prostaglandins4, 325 (1973).

    Article  PubMed  Google Scholar 

  32. S.A. Saeed, P.A. Kendall, N.M. Butt andH.O.J. Collier,On the mode of action and biochemical properties of anti-inflammatory drugs, Biochem. Soc. Trans.7, 655 (1979).

    PubMed  Google Scholar 

  33. G. Segre andS. Hammarstrom,Aspects of the mechanisms of action of benzydamine, in press in Tissue Reactions (1985).

  34. J.S. Lowe,Serum protein changes in rats with arthritis induced by mycobacterial adjuvant, Biochem. Pharmacol.13, 633–641 (1964).

    Article  PubMed  Google Scholar 

  35. H. Berry, J.P. Giroud andD.A. Willoughby, Evidence for an endogenous antigen in the adjuvant arthritic rat. InFuture Trends in Inflammation, pp. 285–286 (EdsG.P. Velo, D.A. Willoughby andJ.P. Giroud). Piccin Medical Books, Padua 1974.

    Google Scholar 

  36. N.J. Zvaifler, Immunopathology of inflammatory diseases: rheumatoid arthritis as an example. InAdvances in Inflammation Research, vol. 7, pp. 1–11 (EdsI. Otterness, R. Capetola andS. Wong). Raven Press, New York 1984.

    Google Scholar 

  37. S.L. Kunkel andS.W. Chensue, Prostaglandins and the regulation of immune responses. InAdvances in Inflammation Research, vol. 7, pp. 93–109 (EdsI. Otterness, R. Capetola andS. Wong). Raven Press, New York 1984.

    Google Scholar 

  38. J. Noordhoek andI.L. Bonta, Mechanism of the anti-inflammatory effect of carrageenin pouch exudate. InFuture Trends in Inflammation, pp. 249–259 (EdsG.P. Velo, D.A. Willoughby andJ.P. Giroud). Piccin Medical Books, Padua 1974.

    Google Scholar 

  39. D.A. Lewis,Endogenous inflammatory proteins, Biochemical Pharmacology, vol. 26, pp. 693–698. Pergamon Press, 1977.

  40. S.A. Saeed, W.J. McDonald-Gibson, J. Cuthbert, J.L. Copas, C. Schneider, P.J. Gardiner, N.M. Butt andH.O.J. Collier,Endogenous inhibitor of prostaglandin synthetase, Nature (Lond.)270, 32–36 (1977).

    Google Scholar 

  41. I.L. Bonta, InInflammation: Mechanisms and Their Impact on Therapy, pp. 121–131 (EdsI.L. Bonta, J. Thompson andK. Brune). Birkhauser Verlag, Basel 1977.

    Google Scholar 

  42. B.S. Shim,Increase in serum haptoglobin stimulated by prostaglandins, Nature (Lond.)259, 326–327 (1976).

    Google Scholar 

  43. A. Pineiro, A.M. Olivito andJ. Uriel,Fixation d'acides gras polyinsatures par l'alphafoetoproteine et la serum albumine de rat. Comparaison avec l'accumulation de ces acides dans le cerveau au cours du developpement post-natal, Comptes Rendus des Seances de l'Academie des Sciences289, 1053–1056 (1979).

    Google Scholar 

  44. B. Silvestrini, P.G. Natali, B. Catanese, G. Barillari andP. Cordiali-Fei,Occurrence of globulin-like migrating blood albumins, or Glimbal, inpathological rat and human sera, Can. J. Biochem.58, 89–92 (1980).

    PubMed  Google Scholar 

  45. K. Ishizaka andD.H. Campbell,Biologic activity of soluble antigen-antibody complexes, J. Immunol.83, 318 (1959).

    PubMed  Google Scholar 

  46. E.L. Opie,On the relation of necrosis and inflammation to denaturation of proteins, J. exp. Med.115, 597 (1962).

    Article  PubMed  Google Scholar 

  47. E.L. Opie,On the relation of inflammation to the chemical constitution of injurious agents on the pharmacology of inflammation, J. exp. Med.117, 425 (1963).

    Article  PubMed  Google Scholar 

  48. P.S. Hench,The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone, Ann. intern. Med.36, 1 (1952).

    PubMed  Google Scholar 

  49. B. Silvestrini, B. Catanese, V. Cioli, S. Burberi andP. Scorza Barcellona,Brewers yeast-induced inflammation in rats: investigation on some humoral and functional changes, Boll. Chim. Farm.106, 385–397 (1967).

    PubMed  Google Scholar 

  50. Y. Mizushima, Effect of non-steroidal anti-inflammatory drugs on proteins. InInflammation, pp. 37–44 (EdsB. Silvestrini, S. Tura andW.G. Spector). Excerpta Medica Foundation, Amsterdam 1968.

    Google Scholar 

  51. Y. Mizushima,Simple screening test for antirheumatic drugs, Lancet1, 169 (1965).

    Article  Google Scholar 

  52. Y. Mizushima,Screening test for antirheumatic drugs, LancetII, 443 (1966).

    Article  Google Scholar 

  53. Y. Mizushima, R. Kasukawa andY. Oshima,Chemical properties of necrotizing factor in the serum from rheumatic patients, Acta rheumatol. scand.8, 183 (1962).

    Google Scholar 

  54. Y. Mizushima andH. Suzuki,Interaction between plasma proteins and antirheumatic or new antiphlogistic drugs, Arch. int. Pharmacodyn.157, 115 (1965).

    PubMed  Google Scholar 

  55. Y. Mizushima andT. Nakagawa,Physicochemical and biochemical properties of nonsteroid antirheumatic drugs, Rheumatism20, 16 (1966).

    Google Scholar 

  56. B. Silvestrini, B. Catanese, R. Lisciani andA. Alessandroni,Studies on the mechanism of action of bendazac (AF 983), Arzneim. Forsch.20, 250–253 (1970).

    Google Scholar 

  57. B. Silvestrini, B. Catanese andV. Cioli, Aspects of protein stabilization connected with the research of antirheumatic drugs. InFuture Trends in Inflammation, pp. 193–202 (EdsG.P. Velo, D.A. Willoughby andJ.P. Giroud). Piccin Medical Books, Padua 1974.

    Google Scholar 

  58. B. Catanese, A. Rossi, B. Silvestrini andG. Toschi,Effect of bendazac and phenylbutazone on polymerization of bovine serum albumin, Pharmacol. Res. Commun.8, 549 (1976).

    PubMed  Google Scholar 

  59. B. Silvestrini, V. Cioli andS. Burberi,Pharmacological properties of bendazac (AF 983) with particular reference to its topical action on some experimental inflammatory processes, Arzneim. Forsch.19, 30–36 (1969).

    Google Scholar 

  60. V. Cioli, C. Corradino, G. Mazzanti andB. Silvestrini,General pharmacological investigations on bendazac lysine, Il Farmaco39, 439–454 (1984).

    Google Scholar 

  61. R. Lisciani, P. Scorza Barcellona andB. Silvestrini,Topical activity of bendazac on experimental burns, Jap. J. Pharmacol.21, 69 (1971).

    PubMed  Google Scholar 

  62. H. Selye, P. Rohan andU.S. Pahk,Humoral conditioning for necrosis. Part I The Conditioning Factors, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.255, 133–141 (1966).

    Article  Google Scholar 

  63. H. Selye andP. Rohan,Humoral conditioning for necrosis. Part II The Challengers, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.255, 142–150 (1966).

    Article  Google Scholar 

  64. G.C. Fuga, M. De Gregorio andR. Milbradt (eds),New Trends in Skin Therapeutics — Non-Steroid Anti-Inflammatory Local Treatment, pp. 1–266. Leonardo Edizioni Scientifiche, Rome 1975.

    Google Scholar 

  65. L. Bonomi, G. Marchini, I. De Franco, S. Perfetti andM. De Gregorio,Bendazac lysine salt in the treatment of cataract — a controlled study, Curr. Ther. Res. Clin. Exp.33, 727–732 (1983).

    Google Scholar 

  66. L.L. Mannucci, D. Doro, M.R. Angi, G. Prosdocimo, L. Zanette, P. Pampinella, A. Zanoni, E. Dal Ri, F. Destro andP. Rizzo Boscolo,Terapia della cataratta presenile e senile. Valutazione clinica del bendazac lisina attraverso uno studio policentrico in condizioni di doppio cieco, Boll. Ocul.62, 87–94 (1983).

    Google Scholar 

  67. M. Testa, G. Iuliano, M. De Gregorio andM. Pioggia,A double-blind clinical study on the anti-cataract effect of bendazac lysine salt, Acta Ther.9, 235–252 (1983).

    Google Scholar 

  68. M. Testa, G. Iuliano, M. De Gregorio andM. Pioggia,A controlled clinical study of bendazac lysine salt in senile cataract, Acta Ther.10, 35 (1984).

    Google Scholar 

  69. R. Caramazza, M. De Gregorio andM. Pioggia,Valutazione clinica controllata del bendazac lisina nella cataratta senile in uno studio policentrico — Analisi dell' effetto di sei mesi di trattamento, Boll. Ocul.64, 71–88 (1985).

    Google Scholar 

  70. G. Boschi, M. Casacci andA. Lia,L'uso del bendazac lisina — bendalina — nella terapia della cataratta, Minerva Oftalmol.24, 227–233 (1982).

    Google Scholar 

  71. R. Leoni andR. Baroncini,Esperienze con bendalina nella terapia della cataratta, Minerva Oftalm.24, 215–226 (1982).

    Google Scholar 

  72. S. Peralta andA. Pescatori,Saggio clinico — terapeutico della bendalina nella cataratta, Il Policlinico6, 495–500 (1982).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology and Pharmacognosy, University of Rome, Italy

    Bruno Silvestrini

Authors
  1. Bruno Silvestrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvestrini, B. Animal models for the study of atypical anti-inflammatory agents. Agents and Actions 17, 329–337 (1986). https://doi.org/10.1007/BF01982638

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01982638

Keywords

Search

Navigation